EPO and colorectal cancer: However, although there was no significantly different drop-out rate noted between high-dose recombinant human erythropoietin plus oral iron supplement group and the placebo/control groups, the safety of high-dose recombinant human erythropoietin in patients with colorectal cancer should be cautious.